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Abstract
Background: Phosphorylation by the phospho-inositide-dependent kinase 1 (PDK1) is essential for many growth factor-
activated kinases and thus plays a critical role in various processes such as cell proliferation and metabolism. However, the
mechanisms that control PDK1 have not been fully explored and this is of great importance as interfering with PDK1
signaling may be useful to treat diseases, including cancer and diabetes.
Methodology/Principal Findings: In human cells, few mono-ubiquitinated proteins have been described but in all cases
this post-translational modification has a key regulatory function. Unexpectedly, we find that PDK1 is mono-ubiquitinated in
a variety of human cell lines, indicating that PDK1 ubiquitination is a common and regulated process. Ubiquitination occurs
in the kinase domain of PDK1 yet is independent of its kinase activity. By screening a library of ubiquitin proteases, we
further identify the Ubiquitin-Specific Protease 4 (USP4) as an enzyme that removes ubiquitin from PDK1 in vivo and in vitro
and co-localizes with PDK1 at the plasma membrane when the two proteins are overexpressed, indicating direct
deubiquitination.
Conclusions: The regulated mono-ubiquitination of PDK1 provides an unanticipated layer of complexity in this central
signaling network and offers potential novel avenues for drug discovery.
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Introduction
Growth factors such as insulin promote fundamental cellular
processes such as proliferation and survival through the activation
of signaling cascades involving numerous protein kinases. Of these,
the phosphoinositide-3 kinase (PI3K) and the phosphoinositide-
dependent kinase 1 (PDK1) play a critical role [1]. Upon
activation, PI3K generates second messenger molecules consisting
of phosphoinositides that prime members of the AGC superfamily
of protein kinases for activation. At least twenty-three of the AGC
kinases require phosphorylation by PDK1 at a conserved residue
in their activation loop (also called T-loop), including central
enzymes such as the proto-oncogene AKT, Protein Kinase C
(PKC) and the p70 S6 kinase (S6K) [2,3,4,5]. Together, these and
other downstream kinases coordinate cell growth, proliferation,
survival and metabolism and they are frequently found deregu-
lated in many diseases such as cancer and diabetes [6,7,8,9].
The mechanisms that keep PDK1 activity in check are not fully
investigated. Yet, these are of great interest as the ability to
interfere with the activation of its target kinases would be of great
therapeutic importance. Given that PDK1 is such an important
kinase, it is remarkable that it is found constitutively active due to
in trans autophosphorylation of its T-loop residue [10]. Indeed,
regulation of substrate accessibility is thought to be a major
mechanism whereby PDK1 activity is controlled. In the case of
AKT, this is achieved by recruitment to phospholipids generated
by PI3K at the plasma membrane via the Pleckstrin Homology
(PH) domains of both kinases. For other AGC kinases such as S6K
and serum- and glucocorticoid-induced kinase (SGK), a priming
phosphorylation on the hydrophobic motif by other kinases
stimulates interaction with the PDK1 interacting fragment (PIF)
pocket near the catalytic domain of PDK1, thereby facilitating T-
loop phosphorylation [5,11,12]. PDK1 has also been described to
shuttle between the nucleus and the cytoplasm in a growth factor
dependent manner but the significance of this in terms of target
activation has not been addressed [13,14]. Given the central role
of PDK1 in the regulation of many downstream effectors, it is
likely that additional regulatory mechanisms remain to be
discovered.
The addition of the small molecule ubiquitin to proteins plays a
critical role in essentially all biological processes. Indeed, defects
in this control mechanism can cause many diseases including
cancer [15,16,17]. The addition of polyubiquitin chains to
proteins was originally identified as a mechanism for targeting
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recently been shown that selective mono-ubiquitination or
alternative ubiquitin chains can also regulate protein activity
[18,19,20,21,22,23,24]. These non-proteolytic functions of ubi-
quitination play diverse roles in DNA damage repair, protein
trafficking and localization and activation of signal transduction
pathways. Like phosphorylation, ubiquitination is reversible and
mediated by deubiquitinating enzymes (DUBs) that cleave the
isopeptide bond at the carboxy terminus of ubiquitin [25].
Furthermore, DUBs have also become actively studied drug
targets for cancer therapy [26,27].
Various PI3K pathway components are regulated by ubiquiti-
nation, including AKT and PTEN [28,29,30]. However, for
PDK1 no post-translational modification other than phosphory-
lation has been described. Here, we show that PDK1 is mono-
ubiquitinated and that this modification occurs in the amino-
terminal kinase domain. In addition, a cDNA library consisting of
DUBs was screened for novel regulators of PDK1 ubiquitination
and USP4 was identified as a potential modulator of PDK1
ubiquitination.
Results
PDK1 is modified by mono-ubiquitination
To investigate if PDK1 is ubiquitinated, we isolated ubiquitin-
modified proteins from HEK293T cells by His-tagged ubiquitin
pull-down under denaturing conditions (Figure 1A). Using a PDK1
specific antibody, we observed several distinct bands of which the
most abundant migrated approximately 5–10 kDa higher than the
major PDK1 isoform. This suggested that PDK1 is modified by a
single ubiquitin moiety and the presence of multiple bands is in
agreement with previous reports concerning PDK1 splice isoforms
[31]. As mono-ubiquitination generally affects protein functionality
and therefore may play a role in PDK1 regulation, we wished to
explore this observation further. We henceforth refer to the
ubiquitin-modified form of PDK1 as Ub-PDK1.
Figure 1. PDK1 is mono-ubiquitinated in a variety of cell lines. A: HEK293T cells were transfected with 66His-tagged ubiquitin and
ubiquitinated proteins were isolated with nickel beads under denaturing conditions. Pull-downs and input were analyzed with an antibody
recognizing PDK1. Ub-PDK1 indicates ubiquitin-modified PDK1 species; asterisk indicates unspecific cross-reacting band. B: HEK293T cells were
transfected with a V5-tagged PDK1 cDNA and V5-PDK1 was immunoprecipitated. Immunoprecipitations (IP) and input were immunoblotted with a
V5 antibody. C: HEK293T cells were co-transfected as indicated with HA-tagged ubiquitin and V5-PDK1. Immunoprecipitation of HA-ubiquitin and
input were immunoblotted with a V5 antibody. D: HEK293T cells were co-transfected as indicated and whole cell extracts were probed with anti-V5
or anti-HA antibody. E: HEK293T cells were transfected with V5-tagged PDK1 or a linear PDK1-ubiquitin C-terminal fusion protein. The whole cell
extracts were probed with anti-V5 antibody. F: Endogenous PDK1 was immunoprecipitated from HEK293T cells and blotted with anti-PDK1 antibody.
The following controls were used: anti-PDK1 antibody only, sepharose beads only, anti-lgG2a control antibody with beads. G: Lysates from the
indicated cell lines were subjected to PDK1 immunoprecipitation. Immunoprecipitations were immunoblotted with a PDK1 antibody.
doi:10.1371/journal.pone.0031003.g001
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ubiquitinated PDK1, we first expressed V5-tagged PDK1 and
performed V5 immunoprecipitation. As expected, immunoblot-
ting with an anti-V5 antibody revealed several PDK1 bands, one
of which migrated at the predicted molecular weight of mono-
ubiquitinated PDK1 (Figure 1B). Co-expression of HA-tagged
ubiquitin and V5-PDK1 further enhanced ubiquitination such
that Ub-PDK1 became visible in the whole cell extract (Figure 1C,
lower panel) and anti-HA immunoprecipitation confirmed that the
slower migrating PDK1 band corresponds to Ub-PDK1
(Figure 1C, upper panel). Furthermore, co-expression of a lysine-
less ubiquitin mutant (K0) that cannot mediate chain formation
resulted in a similar Ub-PDK1 pattern, further indicating that the
observed band is due to a single ubiquitin moiety (Figure 1D). In
agreement with this, a linear PDK1-ubiquitin C-terminal fusion
protein migrated at the same position in the gel as Ub-PDK1
(Figure 1E).
To determine whether we could detect endogenous Ub-PDK1,
we performed PDK1 immunoprecipitation experiments. Immu-
noblotting with an anti-PDK1 antibody revealed a clear, albeit
minor Ub-PDK1 band at the predicted molecular weight
(Figure 1F). Importantly, varying levels of endogenous Ub-
PDK1 were observed in a variety of cell lines derived from
different tumor types (Figure 1G). Together, these experiments
indicate that PDK1 mono-ubiquitination is a common and
differentially regulated post-translational modification.
Mono-ubiquitination of PDK1 occurs in the kinase
domain
To further characterize this novel post-translational modifica-
tion, we analyzed its site of attachment using a PDK1 deletion
mutant (Figure 2A). Cells transfected with full-length PDK1 or just
the kinase domain, were analyzed for Ub-PDK1 (a PDK1 mutant
lacking the kinase domain was not stably expressed and thus not
included in this experiment). A band migrating approximately 5–
10 kDa higher than the kinase domain was detectable, suggesting
that this domain is ubiquitinated (Figure 2B). Indeed, this was
confirmed to be ubiquitinated PDK1 by HA-ubiquitin immuno-
blot (Figure 2C). In this experiment we detected a second Ub-
PDK1 band (labeled Ub-PDK1(2)) migrating some 5–10 kDa
above the mono-ubiquitinated PDK1, indicating conjugation of
two ubiquitin moieties onto a single PDK1 molecule. However, we
did not detect conjugation of multiple ubiquitin polypeptides to
endogenous PDK1 in the absence of exogenous ubiquitin,
suggesting that this only occurs upon overexpression (Figure 1F).
To exclude the possibility that ubiquitin can also conjugate to
the PH domain and to further corroborate the observation that
ubiquitination occurs in the kinase domain, we mutated all 27
Figure 2. The kinase domain of PDK1 is mono-ubiquitinated. A: Overview of the PDK1 constructs used in the figure. PDK1 consists of an
amino-terminal kinase domain (KD) and a carboxyl-terminal Pleckstrin Homology (PH) domain. The K-less mutant has all 27 lysine residues (K)
mutated to arginines (R). B: HEK293T cells were transfected as indicated and PDK1 was immunoprecipitated with anti-V5 beads.
Immunoprecipitations (IP) and input were immunoblotted with anti-V5 antibody. C: HEK293T cells were transfected as indicated and proteins
were immunoprecipitated with anti-V5 beads. Immunoprecipitations (IP) were immunoblotted with V5 and HA antibodies. D: HEK293T cells were
transfected and the lysine-less mutant of PDK1 was immunoprecipitated with anti-V5 beads and probed with anti-V5 antibody. The wild type
construct (WT, V5-PDK1) was used as a control.
doi:10.1371/journal.pone.0031003.g002
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keeping the PH domain intact (Figure 2A). As expected, this K-less
mutant was not mono-ubiquitinated (Figure 2D). Thus, ubiquiti-
nation of PDK1 occurs in the kinase domain.
Evolutionary conserved lysine residues are not
ubiquitinated
PDK1 comprises 38 lysine residues, each of which could
potentially form an isopeptide bond with an ubiquitin molecule.
Unfortunately, mutating back each single arginine residue in the
K-less mutant to lysine did not restore mono-ubiquitination (not
shown). Next, we mutated twelve of the lysine residues conserved
between worms, fruit fly, mouse and humans to investigate if any
of these would be required for PDK1 mono-ubiquitination.
Mutation of K441 and K492/494 resulted in reduced PDK1
protein expression when compared to the GFP transfection
control, explaining the reduction in Ub-PDK1 in these samples
and indicating that these lysines are not the principal conjugation
residues (Figure 3A). Also mutation of the other conserved lysines
did not result in a dramatic change of Ub-PDK1. Furthermore,
mass spectrometry analysis of purified and trypsin digested Ub-
PDK1 was unable to identify the target residue, despite detection
of the great majority of predicted tryptic peptides (not shown). A
potential explanation for these results may be that PDK1 can be
ubiquitinated on various redundant lysine residues, as has been
shown for AKT, p53 and Cyclin B, thereby making both the
genetic and biochemical approach to identify the site(s) highly
challenging [28,32,33].
Ub-PDK1 is nuclear and cytoplasmic, binds phospholipids
and mono-ubiquitination is not dependent on kinase
activity
PDK1 shuttles between the nucleus and the cytoplasm in a
CRM1-dependent and growth factor regulated manner but the
functional significance of this remains unclear [13,14]. As mono-
ubiquitination has been reported to regulate subcellular localiza-
tion, we investigated a potential role for PDK1 mono-ubiquitina-
tion in this process. Cells were transfected with PDK1 to enable
detection of mono-ubiquitinated PDK1 by immunoblotting, and
subsequently fractionated into nuclear, cytoplasmic and mem-
brane fractions. Ub-PDK1 was found to be equally distributed
over the nuclear, cytoplasmic and membrane fractions (Figure 3B).
As mentioned, PDK1 is recruited to the plasma membrane via
its association with phospholipids such as PIP3, where it is known
to function in phosphorylating target proteins. To determine
whether PDK1 mono-ubiquitination plays a role in binding to the
plasma membrane, we incubated cell lysates from cells transfected
with V5-tagged PDK1 with phospholipid-coated beads. The ratio
PDK1:Ub-PDK1 in the input and lipid bead bound fraction was
very similar (compare lanes 2 and 5), indicating that Ub-PDK1
binds equally well to phospholipid-coated beads as unmodified
PDK1. Furthermore, a PDK1 PH domain point mutant that
impairs phospholipid binding [34] was still mono-ubiquitinated,
indicating that lipid binding is not a pre-requisite for ubiquitina-
tion (Figure 3C). Together, these observations indicate that PDK1
mono-ubiquitination is not involved in membrane binding, at least
under these conditions.
Figure 3. Ub-PDK1 localizes to all cellular compartments, binds phospholipids and mono-ubiquitination is not dependent on
kinase activity. A: HEK293T cells were co-transfected with wild type V5-PDK1 (WT) or the indicated lysine mutants and GFP. Whole cell extracts
were blotted and probed with anti-V5 and GFP that served as a transfection efficiency control. B: Cell fractionation analysis of HEK293T cells
transfected with V5-tagged PDK1 (Cyt=cytoplasmic, Mem=membrane bound, Nuc=nuclear). Ub-PDK1 was detected with a V5 antibody. The
HSP90, Histone H1 (H1) and Actin antibodies were used as controls. C: HEK293T cells were transfected as indicated and PDK1 was pulled down using
phospholipid-coated (PIP3) or control beads. Pull-downs and input were probed with anti-V5 antibody. D: HEK293T cells were transfected and the
catalytically inactive mutant K110R of PDK1 was immunoprecipitated with anti-V5 beads and probed with anti-V5 antibody. The wild type construct
(WT, V5-PDK1) was used as a control. E: HEK293T cells were transfected as indicated and PDK1 was immunoprecipitated with anti-V5 beads.
Immunoprecipitations (IP) were analyzed with an antibody recognizing phosphorylated PDK1 at the Ser241 site.
doi:10.1371/journal.pone.0031003.g003
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dependent on its kinase activity. A catalytically inactive PDK1
K110R point mutant [35] was found to be comparably mono-
ubiquitinated as wild type PDK1 and analysis with a phospho-
specific antibody showed that both PDK1 species were phosphor-
ylated, indicating that kinase activity is not required for PDK1
mono-ubiquitination (Figure 3D and 3E).
USP4 deubiquitinates PDK1 and co-localizes at the
plasma membrane
As mono-ubiquitination does not lead to protein degradation
and can be reverted by deubiquitinating enzymes (DUBs), we
screened a total of 70 DUBs for their ability to inhibit Ub-PDK1
upon overexpression (Figure 4A). Tagged PDK1 and each
individual DUB were co-expressed in HEK293T cells and
analyzed for Ub-PDK1. Although the great majority of DUBs
was expressed at high levels (Figure S1), only the Ubiquitin-
Specific Protease 4 (USP4) reproducibly inhibited Ub-PDK1
(Figure 4A and 4B). Other candidate hits from the screen,
including #24 and #56, failed to show a reproducible reduction
in Ub-PDK1 (Figure S2). A catalytically inactive USP4 mutant
(C311S), in which the active site cysteine 311 residue is mutated to
serine, failed to modulate PDK1 ubiquitination, indicating that the
effect of USP4 on PDK1 is dependent on its deubiquitinase
activity (Figure 4B). Importantly, the inhibitory effect of USP4 on
Ub-PDK1 could also be shown for endogenous PDK1 (Figure 4C
and 4D). In addition, the closely related USP15, which shares 61%
amino acid sequence identity with USP4 [36], had no effect on
Ub-PDK1 levels, further suggesting that the ability of USP4 to
deubiquitinate PDK1 is specific.
To investigate if the effect of USP4 on reducing PDK1
ubiquitination could be mediated by direct deubiquitination, we
asked if USP4 displayed in vitro activity towards Ub-PDK1. Wild
type or catalytically inactive USP4 were immunoprecipitated from
transfected cells and incubated with purified PDK1/Ub-PDK1. A
marked reduction in Ub-PDK1 was evident only in the sample
incubated with wild type USP4, indicating that Ub-PDK1 serves
as a direct substrate (Figure 4E).
To further investigate a potential role of USP4 in PDK1
deubiquitination, we asked if the two proteins interact upon
overexpression. As predicted, MYC-tagged USP4 could be co-
immunoprecipitated with V5-PDK1 in HEK293T cells
(Figure 5A). A direct effect of USP4 on PDK1 was also suggested
by co-localization studies using confocal microscopy. In accor-
dance with previous studies, PDK1 was found to be mainly
cytoplasmic with some additional nuclear staining [13,37].
Interestingly, USP4 and PDK1 co-localized intensely at the
plasma membrane when the two proteins were overexpressed
(Figure 5B). Taken together, these results identify USP4 as a
putative regulator of Ub-PDK1.
Discussion
We identify a novel post-translational modification, mono-
ubiquitination, of PDK1, which plays a central role in signaling via
the PI3K pathway to control many cellular processes. We did not
obtain evidence that PDK1 ubiquitination is regulated by growth
factor signaling. For instance, total Ub-PDK1 did not change
upon stimulation with insulin, EGF or glucose under the
conditions we tested (not shown). Also cellular fractionation did
not reveal a compartment-specific response upon stimulation with
insulin (not shown). Nonetheless, it is plausible that PDK1
ubiquitination is modulated under specific conditions or by certain
stimuli. Indeed, there is ample evidence that mono-ubiquitination
is known to play a crucial role in protein function. For instance,
upon DNA damage, the Fanconi Anemia protein FANCD2 is
mono-ubiquitinated and re-localizes to the chromatin whereas
ubiquitin-modified proliferating cell nuclear antigen (PCNA)
recruits a specific DNA polymerase [38,39].
Furthermore, mono-ubiquitination of tyrosine kinase receptors
triggers receptor endocytosis and p53 mono-ubiquitination
stimulates its nuclear export [40,41]. Indeed, future studies will
undoubtedly reveal a key regulatory function of PDK1 mono-
ubiquitination. This function will be of particular interest as it is
not fully understood how PDK1 orchestrates the activation of its
many substrates [42]. For instance, PDK1 ubiquitination may
modulate binding to adapter molecules and downstream targets or
alter subcellular localization. However, the unavailability of a
PDK1 point mutant that is not ubiquitinated hampered the
investigation of these hypotheses. Indeed, reintroducing single
lysine residues in the lysine-less PDK1 mutant did not restore
mono-ubiquitination perhaps because mutation of all lysines in the
kinase domain precludes interaction with the responsible ubiquitin
ligase. The lack of success of the reverse experiment in which
conserved lysines were mutated to arginines may be explained by
redundancy between target lysines. Perhaps future mass spec-
trometry experiments with alternative proteases will reveal the
ubiquitination site(s) on PDK1 and will enable a systematic
functional analysis.
By screening the great majority of DUBs in the human genome,
we identified USP4 as the only DUB enzyme that reduced PDK1
ubiquitination. This high degree of specificity makes USP4 a
prime candidate as a negative regulator of Ub-PDK1. USP4 has
previously been implicated in a number of processes, including
protein quality control in the endoplasmatic reticulum and p53
and Wnt signaling [43,44,45,46]. Interestingly, USP4 has been
reported to inhibit the kinase TAK1 that is ubiquitinated by the
AKT regulator TRAF6. Thus, USP4 may impinge on the PI3K/
PDK1/AKT pathway at multiple levels. However, we could not
show effects on Ub-PDK1 upon knockdown of USP4, which is
possibly explained by functional redundancy with other DUBs or
low basal activity of endogenous USP4 (not shown).
In summary, we identified mono-ubiquitination as a novel post-
translational modification of PDK1 and propose USP4 as a
candidate negative regulator, adding an additional layer of
complexity to the PDK1 signaling network.
Materials and Methods
Cell lines
The human cell lines were obtained from the American Type
Culture Collection. HEK293T (human embryonic kidney cells),
HeLa (cervix carcinoma), U2OS (osteosarcoma), HaCat (kerati-
nocytes), A549 (alveolar basal epithelial carcinoma), MCF7 (breast
adenocarcinoma), SK-HEP1 and HUH7 (hepatoma) cells were
maintained in Dulbecco’s modified Eagle’s medium. K562
(chronic myelogenous leukemia), A2780 (ovarian carcinoma),
THP-1 (acute monocytic leukemia), SNU-387 and HepG2
(hepatoma) were cultured in RPMI-1640 medium. All media
were supplemented with 10% fetal calf serum and 1% penicillin/
streptomycin at 37uC, 5% CO2 and 95% humidity.
Immunoprecipitation, pull-downs and immunoblotting
For immunoprecipitation and PIP3 (Echelon Biosciences) pull-
down, cell extracts were prepared in RIPA buffer (25 mM Tris-
HCl (pH 7.6), 150 mM NaCl, 1% Tergitol, 0.5% Triton X-100
and 0.1% SDS) or in ELB buffer (0.1% NP-40, 50 mM Hepes,
250 mM NaCl and 5 mM EDTA) supplemented with protease
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lysate was sonicated for 266 seconds on ice, centrifuged at
14.000 rpm for 10 min at 4uC and pre-cleared with 10 ml Protein
A/G agarose beads (Pierce #20421). Subsequent immunoprecip-
itation was performed with 20 ml Protein A/G agarose bead
suspension and 1 mg antibody per 1 ml lysate or pre-coupled
agarose bead suspension (anti-HA agarose, Sigma A2095; anti-V5,
Sigma A7345).
For isolation of His-tagged proteins, cells were lysed under
denaturing conditions (10 mM Tris-HCl (pH 8.0), 6 M Guani-
dine-HCl, 100 mM NaH2PO4 and 1 mM Beta-Mercaptoethanol)
supplemented with N-Ethylmaleimide and sonicated. Lysates were
Figure 4. USP4 deubiquitinates PDK1 in vivo and in vitro.A : HEK293T cells were co-transfected with V5-tagged PDK1 and a DUB cDNA library.
PDK1 was immunoprecipitated with anti-V5 beads and the Ub-PDK1 was detected using a V5 antibody. B: HEK293T cells were co-transfected as
indicated. Proteins were immunoprecipitated with anti-V5 beads and immunoblotted with anti-V5 antibody. Whole cell lysates were probed with a
MYC antibody to verify the expression of USP4 constructs. C: HEK293T cells were transfected with indicated DUBs. Endogenous PDK1 was
immunoprecipitated and immunoblotted with a PDK1 antibody. Whole cell lysates were probed with V5 and FLAG antibodies. D: Quantification of
four independent experiments as in C. Indicated are the mean and standard error of the mean and three asterisks indicate T-test p value,0.001. E:
HEK293T cells were transfected as indicated and USP4 was immunoprecipitated using a MYC antibody. Immunoprecipitations were incubated in vitro
with purified HA-tagged PDK1/Ub-PDK1 as a substrate and immunoblotted with anti-HA antibody. The expression of the USP4 constructs was
verified with anti-MYC antibody.
doi:10.1371/journal.pone.0031003.g004
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washed with imidazole buffer (10 mM imidazole, 25 mM Tris-
HCl (pH 8.0), 150 mM NaCl, 1% NP-40 and 0.1% SDS). Beads
were resuspended in sample buffer and boiled for 3 min at 95uC.
For immunoblotting, proteins were resolved by 4–12% Bis-Tris
polyacrylamide gels (Invitrogen) and transferred to polyvinylidene
difluoride (PVDF) membranes. Membranes were blocked in 2% i-
Block (Applied Biosystem) or 4% BSA for 20 min and probed with
the appropriate antibody overnight at 4uC. Detection of bound
antibodies was performed by incubation with horseradish
peroxidase-conjugated anti-rabbit or anti-mouse antibodies at
room temperature for 1 h followed by ECL according to the
manufacturer’s protocol (ECL-PLUS, GE Health Care).
Antibodies
Anti-PDK1 (sc-17765) and anti-GFP (sc-8334) were purchased
from Santa Cruz. Anti-FLAG (F7425), anti-MYC 9E10 (M4439),
anti-V5 V5-10 (V8012), anti-HA HA-7 (H9658) and anti-Actin
(A2066) were obtained from Sigma. Anti-phospho-specific S241
PDK1 (#3061) and anti-HSP90 (SPS-771) were purchased from
Cell Signaling and Stressgen, respectively. Anti-H1.2 (ab17677)
was obtained from Abcam.
Plasmids and cell transfection
The pcDNA6-PDK1-V5-His vector was generated by cloning a
PCR fragment with EcoRI and XbaI restriction sites (Fwd-primer
59GAATTCGCCAGGACCACCAGCCAG39, Rev-primer 59T-
CACTGCACAGCGGCGTCTCTAGA39) into the pcDNA6
backbone. All other mutants were generated by site-directed
mutagenesis using the Stratagene Dpn1 PCR protocol.
The His-tagged ubiquitin expression vector was created by
cloning human ubiquitin B into pcDNA3 using the restriction sites
BamHI and XbaI. The PDK1-ubiquitin C-terminal fusion protein
was created by PCR amplifying human ubiquitin B and cloning it
39 of PDK1 in pcDNA6-PDK1-V5-His vector using KpnI and
EcoRI.
PDK1kinasedomain(KD) expression vectorwas created by PCR
amplification and cloning into pcDNA6-V5-His using EcoRI and
XbaI. The following primers were used: Fwd-primer 59-GATC-
GAATTCCCACCATGGCCAGGACCACCAGC-39,R e v - p r i m e r
59-GATCTCTAGACGGGTGAGCTTCGGAGGCGTC-39.
HA-tagged ubiquitin expression vector (pRK5-HA-ubiquitin
wild type) and the 68 DUB expression vectors were obtained from
Addgene. cDNAs encoding the full-length USP4-WT and -C311S
proteins in the pcDNA4-MYC-His vectors were kindly provided
by Dr. Kristina Lindsten and subcloned into pcDNA6-V5-His.
The K-less PDK1 mutant was ordered from Mr.Gene (Regens-
burg, Germany). All generated constructs and mutants were
verified by Sanger sequencing.
Cells were transfected using the CaPO4 method or with
Lipofectamine 2000 (Invitrogen) according to manufacturer’s
instructions and cells were harvested between 48 and 72 hours
post-transfection.
Cell fractionation was performed using the ProteoExtract
Subcellular Proteome Extraction Kit (Calbiochem #539791)
according to manufacturer’s protocol.
In vitro deubiquitination assay
MYC-tagged USP4 was immunoprecipitated with anti-MYC
antibody and co-incubated with purified STREP-HA-PDK1/Ub-
PDK1 overnight at 30uC in a final volume for 15 mlo f
deubiquitination buffer (50 mM Hepes (pH 7.6), 100 mM NaCl,
5 mM MgCl2, 5% glycerol, 0.2% Triton X-100, 10 mM DTT
and 2 mM ATP). The reaction mixtures were analyzed by
immunoblotting with the anti-HA antibody.
Confocal microscopy
U2OS cells were plated on glass coverslips in 6-well dishes and
transfected with 4 mg cDNA using Lipofectamine 2000. After
48 hours, cells were fixed with 4% paraformaldehyde at room
temperature for 15 min, permeabilized with 0.1% Triton X-100,
blocked with 3% bovine serum albumin-phosphate-buffered
saline solution and incubated with anti-V5 (Invitrogen R960-
25) or anti-MYC 9E10 (Sigma C3956). After extensive washing,
cells were incubated with Alexa-488- (Invitrogen A11001) and
Alexa-564-conjugated (Invitrogen A10040) secondary antibodies
or DAPI for 1 h. Coverslips were mounted onto slides with
ProLong Gold (Molecular Probes). Immunofluorescence-stained
cells were visualized with a Leica DMI6000B confocal micro-
scope and images were captured with LAS AF software, version
2.3.0.
Figure 5. USP4 and PDK1 interact and co-localize at the plasma
membrane. A: HEK293T cells were transfected as indicated and PDK1
was immunoprecipitated with anti-V5 beads. Immunoprecipitations (IP)
and input were probed with anti-V5 and MYC antibodies. B: Confocal
images from transfected U2OS cells stained with V5-PDK1 (green) and
MYC-USP4 (red) antibodies. DNA was visualized by DAPI.
doi:10.1371/journal.pone.0031003.g005
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Figure S1 The majority of DUB cDNA library is
expressed in HEK293T cells. Cells were co-transfected with
V5-tagged PDK1 and a DUB cDNA library. Whole cell lysates
were probed with FLAG and MYC antibodies to verify the
expression of DUBs.
(PDF)
Figure S2 Only USP4 shows a reproducible reduction in
Ub-PDK1. HEK293T cells were co-transfected with V5-tagged
PDK1 and indicated DUB cDNA clones. PDK1 was immuno-
precipitated with anti-V5 beads and the Ub-PDK1 was detected
using a V5 antibody. The normalized Ub-PDK1:PDK1 ratio is
indicated below each lane. Whole cell lysates were probed with
MYC and FLAG antibodies to verify the expression of DUBs.
Asterisks indicate unspecific cross-reacting bands.
(PDF)
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